Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trialArndt Vogel, Martha M. Kirstein, Gunnar Folprecht et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 51
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?Lena Weiss, Michael Haas, Volker Heinemann et al.|Clinical & Translational Oncology|2023Cited by 2